Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
There's no money to replace most of NC students' laptops. What are schools doing about it?
Recommended
Ask the Meteorologist: What is a microburst & how did it cause damage in Wake, Johnston counties Sunday?
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Janux Therapeutics Inc
(NQ:
JANX
)
43.42
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Janux Therapeutics Inc
< Previous
1
2
3
4
5
Next >
$27.5M Bet On Block? Check Out These 3 Stocks Insiders Are Buying
November 14, 2023
Although U.S. stocks closed mixed on Monday, there were a few notable insider trades.
Via
Benzinga
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 07, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics: Q1 Earnings Insights
May 09, 2023
Via
Benzinga
Janux Therapeutics's Return On Capital Employed Overview
December 22, 2022
Via
Benzinga
Why Janux Therapeutics Shares Rose 33.1% This Week
October 22, 2022
The clinical-stage biotech company just began its first clinical trial.
Via
The Motley Fool
Becton, Dickinson and Company, Applied Digital, POSCO And Other Big Stocks Moving Higher On Monday
July 24, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Janux Therapeutics' Stock Is Currently Undervalued, Analyst Highlights Prostate Cancer Candidate Potential
July 17, 2023
Janux Therapeutics Inc (NASDAQ: JANX) announced interim Phase 1 clinical data for PSMA-TRACTr JANX007 in adult subjects with metastatic castration-
Via
Benzinga
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
July 17, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
July 17, 2023
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
June 05, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 09, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
April 24, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
April 20, 2023
From
Janux Therapeutics
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2023
April 06, 2023
Via
Benzinga
7 Biotech Stocks That Could Be the Next Big Thing
March 15, 2023
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.
Via
InvestorPlace
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 10, 2023
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
February 14, 2023
From
Janux Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
February 09, 2023
Via
Benzinga
Why WestRock Company Are Trading Lower By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
February 01, 2023
Gainers Versus Systems Inc. (NASDAQ: VS) surged 270% to $2.26 after the company announced it will partner with Resolve to bring generative AI and gamification to customer payments and credit...
Via
Benzinga
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
December 27, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics to Present at Upcoming Investor Conferences in November
November 22, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
7 Short-Squeeze Stocks for Bold Contrarians to Consider
November 21, 2022
While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists.
Via
InvestorPlace
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 10, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
October 12, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
7 Short-Squeeze Stocks to Buy for Contrarian Investors
October 12, 2022
The pessimists may have bitten off more than they can chew for these intriguing contrarian market ideas.
Via
InvestorPlace
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
September 23, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
September 29, 2022
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...
Via
Benzinga
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
September 28, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.